An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch.
We investigated the pharmacokinetics and safety profiles of a newly developed combined ethinylestradiol (EE)/gestodene (GSD) transdermal contraceptive patch after a single-dose administration and compared with the market available tablet formulation in healthy adult subjects. An open-label, two-period comparative study was conducted in 12 healthy women volunteers. A single dose of the study combined EE/GE transdermal contraceptive patch and oral tablet (Milunet®) were administered. Blood samples at different time points after dose were collected, and concentrations were analyzed. A reliable, highly sensitive and accurate high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC/MS/MS) assay method was developed in this study to determine the plasma concentrations of EE and GSD. Compared to the tablet, the study patch had a significantly decreased maximum plasma concentration (Cmax), extended time to reach theCmaxand half-life, as well as increased clearance and apparent volume of distribution. The half-lives of EE and GSD of the patch were 3.3 and 2.2 times, respectively, than the half-life of the tablet. The areas under the plasma concentration-time curve (AUCs) of EE and GSD of the patch were 8.0 and 16.2 times, respectively, than the AUC of the tablet. No severe adverse event was observed during the whole study, and the general safety was acceptable. In conclusion, compared to the oral tablet Milunet, the study contraceptive patch was well tolerated and showed potent drug exposure, significant extended half-life and stable drug concentrations.
Department of Pharmacy.
Chao
C
Zhang
Institute of Clinical Trial, Peking University Third Hospital, Beijing, People's Republic of China.
Haiyan
H
Li
Department of Pharmacy.
Xin
X
Xiong
Department of Pharmacy.
Suodi
S
Zhai
Institute of Clinical Trial, Peking University Third Hospital, Beijing, People's Republic of China.
Yudong
Y
Wei
Institute of Clinical Trial, Peking University Third Hospital, Beijing, People's Republic of China.
Shuang
S
Zhang
Department of Pharmacy.
Yuanyuan
Y
Zhang
Institute of Clinical Trial, Peking University Third Hospital, Beijing, People's Republic of China.
Lin
L
Xu
Department of Pharmacy.
Li
L
Liu
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D004339:Drug Compounding; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D009652:Norpregnenes / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics*; D013607:Tablets; D057968:Transdermal Patch; D055815:Young Adult
D003271:Contraceptive Agents, Female; D009652:Norpregnenes; D013607:Tablets; C033273:Gestodene; D004997:Ethinyl Estradiol
ethinylestradiol/gestodene; pharmacokinetics; safety; transdermal contraceptive patch